



Canada's Drug and
Health Technology Agency

L'Agence des médicaments et des
technologies de la santé au Canada

Committee Name: pCODR Expert Review Committee (pERC)

Dr. Phillip Blanchette – Conflict of Interest Disclosure (May 2023)

Dr. Phillip Blanchette is a member of the Ontario Health-Cancer Care Ontario Breast Cancer Disease Site Drug Advisory Committee and the National Study Chair with the Canadian Cancer Clinical Trials Group. He previously authored breast cancer guidelines.